Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FAMPRIDINE

All products: not a benefit

Taro-Fampridine · DIN 02482398 · 10mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Fampridine · DIN 02482398 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2020-12-18 Health Canada: Marketed since 2020-11-24 · brand TARO-FAMPRIDINE · ATC N07XX07 FAMPRIDINE · form Tablet (extended-release) · route Oral · ingredients FAMPRIDINE 10 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97285 · Verify on the e-Formulary ↗ (DIN 02482398)

Source record
DIN 02482398: Taro-Fampridine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 929200006; group id 1048; item number 2403; lccId None; manufacturer id TAR Source form: ER Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $8.4730; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482398 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97285
Interchangeable products
Fampyra · DIN 02379910 · not recorded PMS-Fampridine · DIN 02496216 · not recorded
Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-10-02, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482398
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (92:92 Other Miscellaneous Therapeutic Agents) and how they are covered

Matched class: 92:92 Other Miscellaneous Therapeutic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 92:92 Other Miscellaneous Therapeutic Agents

ABOBOTULINUM TOXIN A

· 2 products · Limited Use, codes 130, 412, 413 · strengths: 300U/Vial, 500U/Vial · Pd Inj-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:92
Full class listing Related classes: 92:20 Biologic Response Modifiers, 92:36 Disease-Modifying Antirheumatic Agents, 92:44 Immunosuppressive Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS FAMPYRA (fampridine) extended-release tablets are indicated for: • the symptomatic improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 3.5-7). The initial prescription should be for no more than 4 weeks, and assessment for improvement in walking should be carried out within that timeframe (see 4 DOSAGE AND ADMINISTRATION). FAMPYRA should only be prescribed by (or following consultation with) clinicians who are experienced in the management of multiple sclerosis and who are knowledgeable of the efficacy and safety profile of FAMPYRA and are able to discuss the benefits/risks with patients. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: Renal function should be checked in elderly patients before starting treatment with FAMPYRA and monitored regularly. Use in patients with moderate or severe renal impairment is contraindicated (see 2 CONTRAINDICATIONS; 7.1 WARNINGS AND PRECAUTIONS Special Populations). https://pdf.hres.ca/dpd_pm/00082427.PDF PM date: NOV 03, 2025 Source product: FAMPYRA; DIN 02379910; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Taro-Fampridine · DIN 02482398 Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-10-02, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482398

Check this DIN again

Other review policies

For Taro-Fampridine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026